Project Grant R01CA298628
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $628K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
- Federal Grant Award Summary The University of Iowa received a $2,185,934 Project Grant from the National Cancer Institute (NCI) under the Cancer Centers Support Grants program (CFDA 93.397), awarded August 28, 2025, with completion targeted for July 31, 2030. This Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer award supports innovative translational research addressing neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs)—rare, orphan cancers...
- Federal Grant Award Summary The University of Iowa received a $155,500 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded July 18, 2025, with a completion date of June 30, 2027. The grant supports research establishing an in vivo Sleeping Beauty (SB) transposon mutagenesis screen in a nevi-prone zebrafish model to identify and characterize novel genetic drivers of melanomagenesis. The research addresses a critical...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $542,644 Project Grant effective April 1, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports the development and preclinical evaluation of radiation-guided antibody-drug conjugates (ADCs) targeting Tax-Interacting Protein 1 (TIP1) as a novel therapeutic approach for non-small cell lung cancer (NSCLC). The research leverages a breakthrough...
- Federal Grant Award Summary The National Cancer Institute awarded Johns Hopkins University a $591,419 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026 through April 30, 2031. This award supports the development of low molecular weight (LMW) theranostics—a paired diagnostic and therapeutic agent—targeting CD38 (Cluster of Differentiation 38) protein for multiple myeloma treatment and detection. The project deliverables include creation of an...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University $128,228 under the Cancer Research Manpower program (CFDA 93.398) for a two-year project period from July 1, 2025 through June 30, 2027. The project focuses on developing inhalable extracellular vesicles (exosomes) engineered for lung cancer treatment, addressing a critical clinical need given that lung carcinoma remains the leading cause of global cancer incidence and mortality. The research centers on...
- Grant Award Summary The University of Pennsylvania received a $695,205 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct early-phase clinical trials of 211-astatine-meta-astatobenzylguanidine (211At-MABG) for treating neuroblastoma in children and advanced neuroendocrine cancers in adults. The award period runs from June 1, 2025, through May 31, 2030. The research addresses limitations of existing treatments,...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Nebraska Medical Center (UNMC) a Project Grant of $391,186 under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, with a completion date of August 31, 2027. This research project focuses on co-targeting insulin-like growth factor 1 receptor (IGF-1R) and glutaminase in Ewing sarcoma, a pediatric and young adult bone malignancy with poor survival outcomes once...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Southern California a Project Grant totaling $650,450 under the Cancer Detection and Diagnosis Research program (CFDA 93.394), with performance extending from July 1, 2025 through June 30, 2030. This grant supports the development and translational advancement of IMT-423 (MHC-II-restricted CT83-specific CD4-dependent TCRM50A-STEM2 T cells), an innovative T cell receptor (TCR)-engineered CD4+ T cell...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $716,521 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on August 25, 2025, with a completion date of July 31, 2030. This grant funds the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cell therapy for treating small cell lung cancer (SCLC), a disease with exceptionally poor prognosis and limited...